Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide.

Lombardi LR, Kanakry CG, Zahurak M, Durakovic N, BolaƱos-Meade J, Kasamon YL, Gladstone DE, Matsui W, Borrello I, Huff CA, Swinnen LJ, Brodsky RA, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L.

Leuk Lymphoma. 2016;57(3):666-75. doi: 10.3109/10428194.2015.1071488. Epub 2015 Oct 12.

2.

Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study.

Andersson BS, Madden T, Tran HT, Hu WW, Blume KG, Chow DS, Champlin RE, Vaughan WP.

Biol Blood Marrow Transplant. 2000;6(5A):548-54.

PMID:
11071260
3.

Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study.

Andersson BS, Kashyap A, Gian V, Wingard JR, Fernandez H, Cagnoni PJ, Jones RB, Tarantolo S, Hu WW, Blume KG, Forman SJ, Champlin RE.

Biol Blood Marrow Transplant. 2002;8(3):145-54.

4.

Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality.

McCune JS, Batchelder A, Deeg HJ, Gooley T, Cole S, Phillips B, Schoch HG, McDonald GB.

Biol Blood Marrow Transplant. 2007 Jul;13(7):853-62.

5.

Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies.

Williams CB, Day SD, Reed MD, Copelan EA, Bechtel T, Leather HL, Wingard JR, Abbott BL, Abhyankar S, McGuirk JP.

Biol Blood Marrow Transplant. 2004 Sep;10(9):614-23.

6.

Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes.

Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C, Stewart D, Ruether JD, Morris D, Glick S, Gyonyor E, Andersson BS.

Biol Blood Marrow Transplant. 2002;8(9):468-76.

7.

Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality.

Kashyap A, Wingard J, Cagnoni P, Roy J, Tarantolo S, Hu W, Blume K, Niland J, Palmer JM, Vaughan W, Fernandez H, Champlin R, Forman S, Andersson BS.

Biol Blood Marrow Transplant. 2002;8(9):493-500.

8.

Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia.

Pidala J, Kim J, Anasetti C, Kharfan-Dabaja MA, Nishihori T, Field T, Perkins J, Perez L, Fernandez HF.

J Hematol Oncol. 2010 Oct 6;3:36. doi: 10.1186/1756-8722-3-36.

9.

Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia.

Andersson BS, Thall PF, Madden T, Couriel D, Wang X, Tran HT, Anderlini P, de Lima M, Gajewski J, Champlin RE.

Biol Blood Marrow Transplant. 2002;8(9):477-85.

11.

Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies.

Pasquini MC, Le-Rademacher J, Zhu X, Artz A, DiPersio J, Fernandez HF, Mineishi S, Kamishohara M, Mehta J, Nakamura Y, Ratanatharathorn V, Sobecks R, Burkart J, Bredeson C.

Biol Blood Marrow Transplant. 2016 Aug;22(8):1424-1430. doi: 10.1016/j.bbmt.2016.04.013. Epub 2016 May 3.

12.

Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.

Nagler A, Rocha V, Labopin M, Unal A, Ben Othman T, Campos A, Volin L, Poire X, Aljurf M, Masszi T, Socie G, Sengelov H, Michallet M, Passweg J, Veelken H, Yakoub-Agha I, Shimoni A, Mohty M.

J Clin Oncol. 2013 Oct 1;31(28):3549-56. doi: 10.1200/JCO.2013.48.8114. Epub 2013 Aug 26.

PMID:
23980086
13.

Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity.

Bartelink IH, van Reij EM, Gerhardt CE, van Maarseveen EM, de Wildt A, Versluys B, Lindemans CA, Bierings MB, Boelens JJ.

Biol Blood Marrow Transplant. 2014 Mar;20(3):345-53. doi: 10.1016/j.bbmt.2013.11.027. Epub 2013 Dec 4.

14.

Modified busulfan and cyclophosphamide conditioning regimen for allogeneic hematopoietic stem cell transplantation in the treatment of patients with hematologic malignancies.

Zhao XF, Mao XF, Wan DM, Liu W.

Transplant Proc. 2014 Jun;46(5):1531-5. doi: 10.1016/j.transproceed.2014.02.023.

PMID:
24935325
15.

A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimen.

Satwani P, Bhatia M, Garvin JH Jr, George D, Dela Cruz F, Le Gall J, Jin Z, Schwartz J, Duffy D, van de Ven C, Foley S, Hawks R, Morris E, Baxter-Lowe LA, Cairo MS.

Biol Blood Marrow Transplant. 2012 Feb;18(2):324-9. doi: 10.1016/j.bbmt.2011.11.007. Epub 2011 Nov 9.

16.

Comparison of Cyclophosphamide Combined with Total Body Irradiation, Oral Busulfan, or Intravenous Busulfan for Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Lymphoblastic Leukemia.

Mitsuhashi K, Kako S, Shigematsu A, Atsuta Y, Doki N, Fukuda T, Kanamori H, Onizuka M, Takahashi S, Ozawa Y, Kurokawa M, Inoue Y, Nagamura-Inoue T, Morishima Y, Mizuta S, Tanaka J; Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.

Biol Blood Marrow Transplant. 2016 Dec;22(12):2194-2200. doi: 10.1016/j.bbmt.2016.09.007. Epub 2016 Sep 13.

17.

[Comparison of intensified myeloablative conditioning regime without antithymocytic globulin (ATG) with myeloablative conditioning regime for single-unit unrelated umbilical cord blood transplantation in hematological malignancies].

Sun ZM, Liu HL, Wu Y, Geng LQ, Zheng CC, Tang BL, Zhu XY, Tong J, Wang XB, Ding KY, Wan X, Zhang L, Yao W, Zhang XH, Han YS, Yang HZ, Liu X, Zhu WW, Wu JS, Wang ZY.

Zhonghua Yi Xue Za Zhi. 2016 Jul 26;96(28):2214-9. doi: 10.3760/cma.j.issn.0376-2491.2016.28.003. Chinese.

PMID:
27480651
18.

Intravenous busulfan-cyclophosphamide as a preparative regimen before allogeneic hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia.

Tang W, Wang L, Zhao WL, Chen YB, Shen ZX, Hu J.

Biol Blood Marrow Transplant. 2011 Oct;17(10):1555-61. doi: 10.1016/j.bbmt.2011.04.003. Epub 2011 Apr 16.

19.

Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.

Zhang XH, Huang XJ, Liu KY, Xu LP, Liu DH, Chen H, Chen YH, Wang JZ, Han W, Lu DP.

Chin Med J (Engl). 2007 Mar 20;120(6):463-8.

PMID:
17439737
20.

Comparison of new flu-bu12-tg conditioning with the standard bu-cy myeloablative regimen in patients undergoing allogeneic stem cell transplantation for acute myeloid leukemia.

Raida L, Tucek P, Faber E, Vondrakova J, Rusinakova Z, Skoumalova I, Hubacek J, Jarosova M, Katrincsakova B, Pikalova Z, Kurfurst P, Indrak K.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2011 Dec;155(4):327-32. doi: 10.5507/bp.2011.040.

Supplemental Content

Support Center